

**ESPS Peer-review Report**

**Name of Journal:** World Journal of Immunology

**ESPS Manuscript NO:** 9997

**Title:** GM3-containing nanoparticles in immunosuppressed hosts: effect on myeloid-derived suppressor cells

**Reviewer code:** 01021289

**Science editor:** Ling-Ling Wen

**Date sent for review:** 2014-03-10 09:18

**Date reviewed:** 2014-04-10 19:03

CLASSIFICATION	LANGUAGE EVALUATION	RECOMMENDATION	CONCLUSION
<input type="checkbox"/> Grade A (Excellent)	<input checked="" type="checkbox"/> Grade A: Priority Publishing	Google Search:	<input checked="" type="checkbox"/> Accept
<input checked="" type="checkbox"/> Grade B (Very good)	<input type="checkbox"/> Grade B: minor language polishing	<input type="checkbox"/> Existed	<input type="checkbox"/> High priority for publication
<input type="checkbox"/> Grade C (Good)	<input type="checkbox"/> Grade C: a great deal of	<input type="checkbox"/> No records	<input type="checkbox"/> Rejection
<input type="checkbox"/> Grade D (Fair)	language polishing	BPG Search:	<input type="checkbox"/> Minor revision
<input type="checkbox"/> Grade E (Poor)	<input type="checkbox"/> Grade D: rejected	<input type="checkbox"/> Existed	<input type="checkbox"/> Major revision
		<input type="checkbox"/> No records	

**COMMENTS TO AUTHORS**

This review article summarizes the properties of the VSSP for the immunomodulatory and antitumor activities. It is concisely written and educational for the immunologists and cancer biologists.

# ESPS Peer-review Report

**Name of Journal:** World Journal of Immunology

**ESPS Manuscript NO:** 9997

**Title:** GM3-containing nanoparticles in immunosuppressed hosts: effect on myeloid-derived suppressor cells

**Reviewer code:** 00457420

**Science editor:** Ling-Ling Wen

**Date sent for review:** 2014-03-10 09:18

**Date reviewed:** 2014-04-17 23:01

CLASSIFICATION	LANGUAGE EVALUATION	RECOMMENDATION	CONCLUSION
<input type="checkbox"/> Grade A (Excellent)	<input type="checkbox"/> Grade A: Priority Publishing	Google Search:	<input type="checkbox"/> Accept
<input checked="" type="checkbox"/> Grade B (Very good)	<input checked="" type="checkbox"/> Grade B: minor language polishing	<input type="checkbox"/> Existed	<input type="checkbox"/> High priority for publication
<input type="checkbox"/> Grade C (Good)	<input type="checkbox"/> Grade C: a great deal of	<input type="checkbox"/> No records	<input type="checkbox"/> Rejection
<input type="checkbox"/> Grade D (Fair)	language polishing	BPG Search:	<input checked="" type="checkbox"/> Minor revision
<input type="checkbox"/> Grade E (Poor)	<input type="checkbox"/> Grade D: rejected	<input type="checkbox"/> Existed	<input type="checkbox"/> Major revision
		<input type="checkbox"/> No records	

# COMMENTS TO AUTHORS

Comments for the editor: It is a well written review which covers a very complicated area. There are some language errors that might need editing. Comments for the authors: I think this is a good review of a very complicated field although I have some comments. To get a better overview of the effects of VSSP on the different immune cells I would like to see a table summarising the effects in short. The TLR4 agonistic properties of VSSP needs to be commented upon since TLR4 stimulation has been shown to induce tumor growth through stimulation of MDSC recruitment and differentiation in other systems (see DOI: 10.1371/journal.pone.0034207 for one example). A summary of adverse effects of VSSP would be appreciated. Has this compound been tested in phase I alone? In the figure I think the scales have been switched? If not I completely misunderstand the figure. The figure legend needs to explain the main effects of VSSP in "B". All abbreviations need to be explained; i.e OTI, SIINFEKL, CTL and OVA.